Study on SSAO enzyme activity and anti-inflammatory effect of SSAO inhibitors in animal model of inflammation

J Neural Transm (Vienna). 2013 Jun;120(6):963-7. doi: 10.1007/s00702-012-0961-1. Epub 2012 Dec 21.

Abstract

SSAO/VAP-1 participates in the accumulation of leukocytes at the site of inflammation. A new SSAO inhibitor, SzV-1287 was demonstrated to inhibit both acute and chronic inflammation in rats more effectively than the known enzyme inhibitor, LJP-1207. Surprisingly, the SSAO activity was not increased, but decreased both in acute and chronic inflammation. Though experiments are in progress to clarify these findings, the enzyme might play a role in the very early phase of inflammation and be inactivated during leukocyte extravasation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amine Oxidase (Copper-Containing) / metabolism*
  • Animals
  • Arthritis, Experimental / chemically induced
  • Arthritis, Experimental / drug therapy*
  • Carrageenan / toxicity
  • Disease Models, Animal
  • Enzyme Inhibitors / therapeutic use*
  • Functional Laterality
  • Gene Expression Regulation, Enzymologic / drug effects
  • Hydrazines / therapeutic use
  • Inflammation / chemically induced
  • Inflammation / drug therapy*
  • Inflammation / ethnology*
  • Male
  • Oxazoles / therapeutic use*
  • Oximes / therapeutic use*
  • Rats
  • Rats, Wistar
  • Time Factors

Substances

  • 3-(4,5-diphenyl-1,3-oxazol-2-yl)propanal oxime
  • Enzyme Inhibitors
  • Hydrazines
  • N'-(2-phenylallyl)hydrazine
  • Oxazoles
  • Oximes
  • Carrageenan
  • Amine Oxidase (Copper-Containing)